Literature DB >> 26385863

Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy study.

José A Lorente1,2,3, Pablo Cardinal-Fernández4, Diego Muñoz5, Fernando Frutos-Vivar6,7, Arnaud W Thille8, Carlos Jaramillo6, Aida Ballén-Barragán6,7, José M Rodríguez6,7, Oscar Peñuelas6,7, Guillermo Ortiz9, José Blanco9, Bruno Valle Pinheiro10, Nicolás Nin11, María del Carmen Marin12, Andrés Esteban6,7, Taylor B Thompson13.   

Abstract

OBJECTIVE: To demonstrate that among patients with acute respiratory distress syndrome (ARDS), the presence of diffuse alveolar damage (DAD) at histological examination, as compared to its absence, defines a specific subphenotype.
METHODS: We studied 149 patients who died in our ICU with the clinical diagnosis of ARDS according to the Berlin Definition (BD) and who had autopsy examination. We compared the change over time of different clinical variables in patients with (n = 49) and without (n = 100) DAD. A predictive model for the presence of DAD was developed and validated in an independent cohort of 57 patients with ARDS and postmortem examination (21 of them with DAD).
RESULTS: Patients with DAD, as compared to patients without DAD, had a lower PaO₂/FiO₂ ratio and dynamic respiratory system compliance, and a higher SOFA score and INR, and were more likely to die of hypoxemia and less likely to die of shock. In multivariate analysis, variables associated with DAD [odds ratio, 95% confidence interval (CI)] were PaO₂/FiO₂ ratio [0.988 (0.981-0.995)], dynamic respiratory system compliance [0.937 (0.892-0.984)] and age [0.972 (0.946-0.999)]. Areas under the ROC curve (95 % CI) for the classification of DAD using the regression model or the BD were, respectively, 0.74 (0.65-0.82) and 0.64 (0.55-0.72) (p = 0.03). In the validation cohort, the areas under the ROC curve for the diagnosis of DAD were 0.73 (0.56-0.90) and 0.67 (0.54-0.81) for the regression model and the BD, respectively.
CONCLUSIONS: The presence of DAD appears to define a specific subphenotype in patients with ARDS. Targeting patients with DAD within the population of patients with the clinical diagnosis of ARDS might be appropriate to find effective therapies for this condition.

Entities:  

Keywords:  Adult respiratory distress syndrome; Autopsy; Diffuse alveolar damage; Histology; Hyaline membranes; Subphenotype

Mesh:

Year:  2015        PMID: 26385863     DOI: 10.1007/s00134-015-4046-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  31 in total

1.  The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation.

Authors:  Jesús Villar; Jesús Blanco; José Manuel Añón; Antonio Santos-Bouza; Lluís Blanch; Alfonso Ambrós; Francisco Gandía; Demetrio Carriedo; Fernando Mosteiro; Santiago Basaldúa; Rosa Lidia Fernández; Robert M Kacmarek
Journal:  Intensive Care Med       Date:  2011-10-14       Impact factor: 17.440

2.  ARDS: a clinicopathological confrontation.

Authors:  Quentin de Hemptinne; Myriam Remmelink; Serge Brimioulle; Isabelle Salmon; Jean-Louis Vincent
Journal:  Chest       Date:  2008-12-31       Impact factor: 9.410

Review 3.  Biomarkers in acute respiratory distress syndrome.

Authors:  Alexandra Binnie; Jennifer L Y Tsang; Claudia C dos Santos
Journal:  Curr Opin Crit Care       Date:  2014-02       Impact factor: 3.687

4.  Discrepancy between clinical criteria for diagnosing acute respiratory distress syndrome secondary to community acquired pneumonia with autopsy findings of diffuse alveolar damage.

Authors:  Xavier Sarmiento; Juan J Guardiola; Jordi Almirall; Eduard Mesalles; Jose Luis Mate; Manuel Soler; Jordi Klamburg
Journal:  Respir Med       Date:  2011-05-12       Impact factor: 3.415

5.  Neuromuscular blockers in early acute respiratory distress syndrome.

Authors:  Laurent Papazian; Jean-Marie Forel; Arnaud Gacouin; Christine Penot-Ragon; Gilles Perrin; Anderson Loundou; Samir Jaber; Jean-Michel Arnal; Didier Perez; Jean-Marie Seghboyan; Jean-Michel Constantin; Pierre Courant; Jean-Yves Lefrant; Claude Guérin; Gwenaël Prat; Sophie Morange; Antoine Roch
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  Accuracy of clinical diagnosis of acute respiratory distress syndrome in comparison with autopsy findings.

Authors:  Bruno Valle Pinheiro; Fabiana Sayuri Muraoka; Raimunda Violante Campos Assis; Raul Lamin; Sérgio Paulo dos Santos Pinto; Paulo Justiniano Ribeiro; Júlio César Abreu de Oliveira
Journal:  J Bras Pneumol       Date:  2007 Jul-Aug       Impact factor: 2.624

7.  Comparison of clinical criteria for the acute respiratory distress syndrome with autopsy findings.

Authors:  Andrés Esteban; Pilar Fernández-Segoviano; Fernando Frutos-Vivar; José Antonio Aramburu; Laura Nájera; Niall D Ferguson; Inmaculada Alía; Federico Gordo; Fernando Ríos
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

8.  The role of open-lung biopsy in ARDS.

Authors:  Sanjay R Patel; Dimitri Karmpaliotis; Najib T Ayas; Eugene J Mark; John Wain; B Taylor Thompson; Atul Malhotra
Journal:  Chest       Date:  2004-01       Impact factor: 9.410

9.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

10.  Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy.

Authors:  Kuo-Chin Kao; Han-Chung Hu; Chih-Hao Chang; Chen-Yiu Hung; Li-Chung Chiu; Shih-Hong Li; Shih-Wei Lin; Li-Pang Chuang; Chih-Wei Wang; Li-Fu Li; Ning-Hung Chen; Cheng-Ta Yang; Chung-Chi Huang; Ying-Huang Tsai
Journal:  Crit Care       Date:  2015-05-15       Impact factor: 9.097

View more
  30 in total

1.  What do we treat when we treat ARDS?

Authors:  Takeshi Yoshida; John F Boylan; Brian P Kavanagh
Journal:  Intensive Care Med       Date:  2015-12-14       Impact factor: 17.440

2.  Do we need ARDS?

Authors:  Jean-Louis Vincent; Carlos Santacruz
Journal:  Intensive Care Med       Date:  2015-11-10       Impact factor: 17.440

3.  Acute respiratory distress syndrome without identifiable risk factors: A secondary analysis of the ARDS network trials.

Authors:  John S Harrington; Edward J Schenck; Clara Oromendia; Augustine M K Choi; Ilias I Siempos
Journal:  J Crit Care       Date:  2018-06-02       Impact factor: 3.425

4.  The Berlin definition met our needs: not sure.

Authors:  Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2016-03-23       Impact factor: 17.440

5.  Should ARDS be renamed diffuse alveolar damage?

Authors:  B Taylor Thompson; Claude Guérin; Andrés Esteban
Journal:  Intensive Care Med       Date:  2016-03-14       Impact factor: 17.440

6.  Outcome of unexplained acute respiratory distress syndrome with diffuse alveolar damage after lung transplantation.

Authors:  François Stéphan; Vincent Thomas de Montpréville; Coumba Diarra; Catherine Pilorge; Elie Fadel; Maria-Rosa Ghigna
Journal:  Intensive Care Med       Date:  2018-01-20       Impact factor: 17.440

Review 7.  MicroRNAs as biomarkers of acute lung injury.

Authors:  Antonio Ferruelo; Óscar Peñuelas; José A Lorente
Journal:  Ann Transl Med       Date:  2018-01

Review 8.  What every intensivist should know about acute respiratory distress syndrome and diffuse alveolar damage.

Authors:  Fernando Rios; Teresa Iscar; Pablo Cardinal-Fernández
Journal:  Rev Bras Ter Intensiva       Date:  2017-09-28

Review 9.  Imaging the Injured Lung: Mechanisms of Action and Clinical Use.

Authors:  Maurizio Cereda; Yi Xin; Alberto Goffi; Jacob Herrmann; David W Kaczka; Brian P Kavanagh; Gaetano Perchiazzi; Takeshi Yoshida; Rahim R Rizi
Journal:  Anesthesiology       Date:  2019-09       Impact factor: 7.892

Review 10.  [Role of imaging procedures in clarification of complications of pneumonia].

Authors:  K Lampichler
Journal:  Radiologe       Date:  2017-01       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.